Holen Sie sich die Stockscreener-App
64.24
1.56%
-1.02
Handel nachbörslich:
64.24
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$65.26
Offen:
$65.28
24-Stunden-Volumen:
4.07M
Relative Volume:
0.80
Marktkapitalisierung:
$24.72B
Einnahmen:
$4.66B
Nettoeinkommen (Verlust:
$836.30M
KGV:
30.69
EPS:
2.093
Netto-Cashflow:
$1.08B
1W Leistung:
-5.67%
1M Leistung:
-8.25%
6M Leistung:
-15.72%
1J Leistung:
-6.19%
1-Tages-Spanne:
$63.82
$65.78
1-Wochen-Bereich:
$63.82
$68.94
52-Wochen-Spanne:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
64.24 | 25.12B | 4.66B | 836.30M | 1.08B | 2.093 |
|
ABT
Abbott Laboratories
|
108.03 | 187.91B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
336.77 | 129.05B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.14 | 112.19B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.13 | 101.72B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
81.81 | 49.14B | 6.07B | 1.06B | 1.34B | 1.8063 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Eingeleitet | Evercore ISI | In-line |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
Mizuho raises DexCom (DXCM) price target to $90 from $78 after earnings beat - MSN
Swiss National Bank Trims Stake in DexCom by 4.8% - National Today
Swiss National Bank Sells 56,600 Shares of DexCom, Inc. $DXCM - MarketBeat
Mackenzie Financial Corp Raises Position in DexCom, Inc. $DXCM - MarketBeat
Capital Research Global Investors Trims Holdings in DexCom, Inc. - National Today
Capital Research Global Investors Cuts Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
Analysts Set DexCom, Inc. (NASDAQ:DXCM) PT at $85.18 - National Today
Is DexCom (DXCM) Quietly Reframing Its Innovation Moat With New Boardroom Tech Expertise? - simplywall.st
Sands Capital Management LLC Lowers Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
WINTON GROUP Ltd Lowers Position in DexCom, Inc. $DXCM - MarketBeat
Citigroup Adjusts Price Target on DexCom to $84 From $77, Maintains Buy Rating - marketscreener.com
First Trust Advisors LP Boosts Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026 - Morningstar
Investigation announced for Long-Term Investors in shares of DexCom, Inc. (NASDAQ: DXCM) - openPR.com
2 Growth Stocks to Hold for the Next Decade - The Motley Fool
DexCom Inc (NASDAQ:DXCM): A Prime Example of Growth at a Reasonable Price - ChartMill
Here's Why DexCom (DXCM) is a Strong Growth Stock - Yahoo Finance
DexCom (NASDAQ:DXCM) Given Buy Rating at BTIG Research - MarketBeat
Demystifying DexCom: Insights From 12 Analyst Reviews - Benzinga
Rathbones Group PLC Reduces DexCom Stake by 79.9% - National Today
Rathbones Group PLC Has $9.32 Million Position in DexCom, Inc. $DXCM - MarketBeat
Korea Investment CORP Has $51.79 Million Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
Bell Asset Management Ltd Buys Shares of 31,448 DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Shares Sold by Alamar Capital Management LLC - MarketBeat
DexCom, Inc. (NASDAQ:DXCM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Can DexCom Inc. stock resist market sell offs2026 Opening Moves & Smart Investment Allocation Tips - Naître et grandir
Neuberger Berman Group LLC Buys 324,849 Shares of DexCom, Inc. $DXCM - MarketBeat
Blair William & Co. IL Lowers Holdings in DexCom, Inc. $DXCM - MarketBeat
Bio-Techne, Bruker, DexCom, STERIS, and Teleflex Shares Plummet, What You Need To Know - Yahoo Finance
A Look At Dexcom (DXCM) Valuation After Recent Share Price Swings - Yahoo Finance
Is DexCom Stock Underperforming the Nasdaq? - Yahoo Finance
Fisher Asset Management LLC Sells 23,056 Shares of DexCom, Inc. $DXCM - MarketBeat
DexCom: Gaining Favor, With Useful Tailwinds To Support It Even Further (NASDAQ:DXCM) - Seeking Alpha
Picton Mahoney Asset Management Acquires 26,106 Shares of DexCom, Inc. $DXCM - MarketBeat
CI Investments Inc. Increases Position in DexCom, Inc. $DXCM - MarketBeat
Elo Mutual Pension Insurance Co Has $3.66 Million Stock Position in DexCom, Inc. $DXCM - MarketBeat
Dexcom Executive Chairman Kevin Sayer Returns From Leave - The Globe and Mail
How Adding Google’s Rick Osterloh To Dexcom’s Board (DXCM) Could Reframe Its Investment Story - simplywall.st
Nasdaq 100 Stock Outlook 2026: DexCom vs. Comcast & Warner Bros. DiscoveryNews and Statistics - IndexBox
Champlain Investment Partners LLC Decreases Stake in DexCom, Inc. $DXCM - MarketBeat
Here's How Much You Would Have Made Owning DexCom Stock In The Last 10 Years - Sahm
Intech Investment Management Reduces DexCom Stake - National Today
Rafferty Asset Management Boosts DexCom Holdings - National Today
Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U - Quantisnow
TD Asset Management Boosts DexCom Stake by 16% - National Today
DexCom, Inc. (DXCM) Stock Analysis: 16.91% Potential Upside Amid Robust Growth Metrics - DirectorsTalk Interviews
DexCom (DXCM) Announces Leadership Transition and Compensation D - GuruFocus
American Century Companies Inc. Reduces DexCom Stake - National Today
Kevin Sayer returns as Dexcom (NASDAQ: DXCM) executive chairman - Stock Titan
DexCom, Inc. $DXCM Shares Sold by American Century Companies Inc. - MarketBeat
TD Asset Management Inc Buys 44,770 Shares of DexCom, Inc. $DXCM - MarketBeat
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.66%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):